We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
FDA, 고위험 비근침윤성 방광암에 Imfinzi(더발루맙) + BCG 승인. 재발 위험 32% 감소. 종양비뇨기학의 혁신에 대해 알아보세요.
